Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma.
The therapy, which harnesses immune cells collected from the patient’s own tumours, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs.
For the first time, Northwestern University scientists have discovered it is possible to isolate a tumours' attack cells non-invasively from blood, rather than from tumours.
The finding opens the door for ACT to treat harder-to-reach cancer types and makes it a more viable option for hospitals.
“We started asking questions about whether the immune cells that go into tumours come back out, and if you could find them in the bloodstream,” said Shana O Kelley, the paper’s corresponding author.
“We didn't know if we’d be able to find them or if we could see enough of them to even study them. Sure enough, they’re in the blood. This is the first time these cells have been studied in this context.”
Kelley is the Neena B Schwartz Professor of Chemistry and Biomedical Engineering at the Northwestern University Weinberg College of Arts and Sciences and McCormick School of Engineering, and a professor of biochemistry and molecular genetics at Northwestern University Feinberg School of Medicine.
She also is president of the Chan Zuckerberg Biohub Chicago.
The study, published today in the journal Nature Biomedical Engineering, builds on previous work from Kelley’s lab that was published last year in the same journal.
In the previous study, Kelley and her team treated mice with their own immune cells gathered from a mass, which dramatically shrunk their tumours, compared to traditional cell-therapy methods.
The 2022 paper also detailed the novel method used to isolate and multiply tumour-infiltrating lymphocytes (TILs), a process that efficiently sorts through and harvests cells to recover 400% more than current approaches, ultimately making the anti-cancer response stronger.
By removing and processing melanoma tumours, scientists have found TILs within them.
But sometimes removing tumours to harvest TILs can pose significant risks to patients, leaving no path to harness ACT to fight many types of cancer.
Kelley wondered if TILs might exist elsewhere in the body — outside tumours.
After finding TIL-like lymphocytes — or circulating tumour-reactive lymphocytes (cTRLs) — in animal blood, the team tested whether or not cTRLs had the same ability as TILs to kill tumour cells.
Surprisingly, they did.
To overcome another major stumbling point, after finding and profiling cTRLs, the Kelley lab used its novel technology platform to isolate and then replicate only the best tumour fighters.
Again, cTRLs effectively levelled their competition by engaging in direct, “hand-to-hand” combat with tumour cells.
“Engineering-based tools allow you to do things that open up new areas of biology,” said Shana O Kelley, the paper’s corresponding author.
“We could see using the platform at any major medical centre, so you could reach a significant number of patients. The platform we use to capture cells is very fast, which brings the cost down, and medical centres are comfortable handling blood.”
Scientists also found cTRLs not just in melanoma models, but in colon, lung and breast cancer, each tumour expressing a unique signature that TILs bind to.
Kelley has spun out the new technology into health tech startup CTRL Therapeutics, which will petition the US Food and Drug Administration to move the platform into clinical trials.
“This new breakthrough leads us to ask some exciting questions about how early cTRLs appear in blood,” Kelley said. “Could we diagnose and treat cancer earlier using these cells?”
Kelley also is a member of the International Institute for Nanotechnology, the Chemistry of Life Processes Institute, the Simpson Querrey Institute for BioNanotechnology and the Robert H Lurie Comprehensive Cancer Center of Northwestern University.
The paper’s first author was Zongjie (Daniel) Wang, a University of Toronto professor in the department of electrical and computer engineering.
Source: Northwestern University
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.